Agios taps Bristol-Myers vet Bruce Car to replace retiring CSO
Jackie Fouse has filled another top role as she gets her team at Agios ready for a second decade, plotting follow-ons to its nascent commercial portfolio.
Five months after Agios announced the retirement of longtime CSO Scott Biller, the biotech has found his successor from Bristol-Myers Squibb, which has been remaking its own structure as it absorbs Celgene’s leadership.
In joining Agios, Bruce Car — the pharma giant’s interim head of drug discovery — leaves behind a decades-long career focused on early-stage research work with roles spanning toxicology, drug optimization and translational science. He started out at DuPont Pharmaceuticals a few years before it was acquired by Bristol-Myers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
